People living with HIV (PLWH) face a paradoxical challenge: while antiretroviral therapy (ART) has turned a once-fatal diagnosis into a manageable condition, it has not stopped the biological clock. This population often exhibits “accentuated aging,” developing age-related comorbidities decades earlier than their HIV-negative peers. In a groundbreaking attempt to pivot from treating infection to treating aging itself, researchers in Madrid have released results from the METFORAGING trial—the first long-term, randomized, double-blind study of metformin’s geroprotective potential in non-diabetic PLWH.
The logic is compelling: metformin, a 60-year-old diabetes workhorse, is known to influence the “hallmarks of aging” by activating energy-sensing pathways like AMPK and inhibiting the growth-promoting mTOR pathway. The METFORAGING team recruited 40 virologically suppressed individuals aged 50 and older, dosing them with 1700 mg of metformin daily for nearly two years. To track the results, they didn’t just look at blood sugar; they utilized “epigenetic clocks”—sophisticated algorithms that read DNA methylation patterns to estimate biological age.
The primary outcome, measured by the PhenoAge clock , failed to reach statistical significance, showing a modest difference of just -1.02 years between the metformin and placebo groups. However, the raw data tells a more nuanced story. Across all 11 biomarkers tested—including second-generation clocks like GrimAge V2 and the “pace of aging” estimator DunedinPACE —every single point estimate favored the metformin group.
While the study was underpowered to declare a definitive “cure” for aging, it achieved a critical prerequisite: safety. In a population already managing polypharmacy and chronic inflammation, metformin was exceptionally well-tolerated. No serious adverse events were linked to the drug, and participants maintained high adherence. This pilot serves as a “green light” for larger, elite-level trials, suggesting that while the epigenetic needle moves slowly, it may indeed be moving in the right direction.
Actionable Insights
The METFORAGING trial provides several practical takeaways for the longevity community:
-
Safety in Non-Diabetics: The study confirms that 850 mg of metformin taken twice daily is safe for older non-diabetics over a 96-week period. Fears regarding lactic acidosis or significant hypoglycemia in non-diabetics were not realized in this cohort.
-
Dosing and Interactions: For those on specific ART like dolutegravir , researchers limited the dose to 850 mg once daily due to known drug-drug interactions that increase metformin exposure. This highlights the need for personalized dosing based on existing medication stacks.
-
Adherence Biomarkers: Serum GDF15 levels were confirmed as a reliable biomarker for metformin exposure. Biohackers or clinicians tracking compliance can use GDF15 to verify systemic activity.
-
Expectation Management: Epigenetic clocks in mixed-cell whole blood are “noisy”. Short-term or small-scale use of metformin may not yield a “statistically significant” reversal of biological age on current commercial tests, even if underlying physiological trends are favorable.
-
Frailty Prevention: Metformin did not significantly improve physical performance or frailty scores in this relatively fit group, suggesting its primary value may be as a preventative rather than a restorative agent for physical function.
Context
Open Access Paper: Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial
- Institution: La Paz University Hospital (IdiPAZ).
- Country: Spain (Madrid).
- Journal Name: eClinicalMedicine (Part of The Lancet Discovery Science).
- Impact Evaluation: The impact score (CiteScore/JIF) of this journal is approximately 15.1 to 25.4, evaluated against a typical high-end range of 0–60+ for top general science; therefore, this is a High impact journal.